Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En 6-måneders og 18-måneders randomisert dobbeltstudie som vurderer sikkerhet og effekt av Buntanetap hos deltakere med tidlig AD (DUET-AD)

16. november 2026 oppdatert av: Annovis Bio Inc.

En 6-måneders og 18-måneders prospektiv, randomisert, placebokontrollert, dobbeltblind dobbel klinisk studie som undersøker effektiviteten og sikkerheten til Buntanetap ved behandling av deltakere av tidlig Alzheimers sykdom

The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are:

  • Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13?
  • Does buntanetap/Posiphen improve function as measured by ADCS-iADL?
  • What medical issues do participants have, if any, when taking buntanetap/Posiphen?

Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease.

Participants will:

  • Take buntanetap/Posiphen or a placebo every day for 18 months
  • Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18
  • Complete pre- and post-clinic visit phone calls

Studieoversikt

Status

Aktiv, ikke rekrutterende

Studietype

Intervensjonell

Registrering (Faktiske)

861

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Arizona
      • Chandler, Arizona, Forente stater, 85286
        • MD First Research
      • Phoenix, Arizona, Forente stater, 85004
        • Xenoscience
      • Scottsdale, Arizona, Forente stater, 85258
        • Clinical Endpoints
    • California
      • Anaheim, California, Forente stater, 92805
        • Advanced Research Center
      • Canoga Park, California, Forente stater, 91303
        • Hope Clinical Research
      • Imperial, California, Forente stater, 92251
        • Sun Valley Research
      • Los Angeles, California, Forente stater, 90095
        • Mary S. Easton Center for Alzheimer's Research and Care, UCLA
      • Sacramento, California, Forente stater, 95816
        • UC Davis Alzheimer's Disease Research Center
      • San Marcos, California, Forente stater, 92069
        • The Neuron Clinic
    • Colorado
      • Basalt, Colorado, Forente stater, 81621
        • Mountain Neurological Center
      • Englewood, Colorado, Forente stater, 80113
        • CenExel Rocky Mountain
    • Connecticut
      • Norwalk, Connecticut, Forente stater, 06851
        • Research Center for Clinical Trials
    • Florida
      • Aventura, Florida, Forente stater, 33180
        • Visionary Investigators Network
      • Boca Raton, Florida, Forente stater, 33487
        • SFM Clinical Research
      • Clermont, Florida, Forente stater, 34711
        • K2 Medical Research
      • Daytona Beach, Florida, Forente stater, 32114
        • K2 Medical Research Daytona
      • Fort Myers, Florida, Forente stater, 33912
        • Neuropsychiatric Research Center
      • Hallandale, Florida, Forente stater, 33009
        • Velocity Clinical
      • Jacksonville, Florida, Forente stater, 32216
        • Jacksonville Center for Clinical Research
      • Lady Lake, Florida, Forente stater, 32159
        • K2 Medical Research
      • Lake Worth, Florida, Forente stater, 33462
        • Headlands Research JEM
      • Lakeland, Florida, Forente stater, 33803
        • Accel Research Sites Lakeland (Alcanza)
      • Maitland, Florida, Forente stater, 32751
        • K2 Medical Research
      • Melbourne, Florida, Forente stater, 32940
        • ClinCloud Clinical Research
      • Merritt Island, Florida, Forente stater, 32952
        • Flourish Research/Merritt Island Medical Research
      • Miami, Florida, Forente stater, 33137
        • Miami Jewish Health
      • Naples, Florida, Forente stater, 34102
        • Aqualane Clinical Research
      • New Port Richey, Florida, Forente stater, 34652
        • Suncoast Clinical Research
      • Orlando, Florida, Forente stater, 32832
        • Conquest Research
      • Tampa, Florida, Forente stater, 33609
        • Axiom Brain Health, LLC
      • Winter Park, Florida, Forente stater, 32789
        • Conquest Research
    • Georgia
      • Decatur, Georgia, Forente stater, 30030
        • Accel Neurosciences
      • Gainesville, Georgia, Forente stater, 30501
        • CARE (Center for Advanced Research & Education)
    • Hawaii
      • Honolulu, Hawaii, Forente stater, 96817
        • Hawaii Pacific Neuroscience
    • Illinois
      • Chicago, Illinois, Forente stater, 60612
        • Rush University Medical Center
      • Chicago, Illinois, Forente stater, 60611
        • Re:Cognition Chicago
      • Chicago, Illinois, Forente stater, 60618
        • Charter Research Chicago
      • Chicago, Illinois, Forente stater, 60640
        • Great Lakes Clinical Trials/Flourish Research
      • Springfield, Illinois, Forente stater, 62702
        • Southern Illinois University
    • Indiana
      • Indianaopolis, Indiana, Forente stater, 46256
        • JWM Research
    • Kansas
      • Wichita, Kansas, Forente stater, 37214
        • Ascension via Christi Research
    • Louisiana
      • Metairie, Louisiana, Forente stater, 70006
        • Tandem Intermediate
    • Maryland
      • Pikesville, Maryland, Forente stater, 21208
        • Headlands Research Pharmasite
    • Massachusetts
      • Foxborough, Massachusetts, Forente stater, 02035
        • Neurology Center of New England, PC
      • Plymouth, Massachusetts, Forente stater, 02360
        • Headlands Research Easter Massachusetts
      • Russells Mills, Massachusetts, Forente stater, 02747
        • Mayflower Clinical
      • Springfield, Massachusetts, Forente stater, 01103
        • Elixia MA
    • Michigan
      • Farmington Hills, Michigan, Forente stater, 48334
        • Quest Research Institute
    • Mississippi
      • Flowood, Mississippi, Forente stater, 39232
        • Precise Research Center
    • Missouri
      • Chesterfield, Missouri, Forente stater, 63005
        • Clinical Research Professionals - Headlands Research
    • Nevada
      • Las Vegas, Nevada, Forente stater, 89121
        • Oasis Clinical Trials LLC
    • New Jersey
      • Toms River, New Jersey, Forente stater, 08755
        • Cenexel Advanced Medical Research of New Jersey (AMRI)
      • West Long Branch, New Jersey, Forente stater, 07764
        • Advanced Clinical Institute
    • New York
      • Amherst, New York, Forente stater, 14226
        • Dent Neurologic Institute
      • Brooklyn, New York, Forente stater, 11235
        • SPRI
      • Lake Success, New York, Forente stater, 11042
        • Neurological Associates of Long Island
      • New York, New York, Forente stater, 10003
        • New York Neurology Associates
      • Staten Island, New York, Forente stater, 10314
        • Richmond Behavioral Associates
      • Syracuse, New York, Forente stater, 13210
        • Ichor Research
    • North Carolina
      • Durham, North Carolina, Forente stater, 27705
        • Duke University
      • Matthews, North Carolina, Forente stater, 28105
        • AMC Research/Flourish Research
    • Ohio
      • Beavercreek, Ohio, Forente stater, 45432
        • American Clinical Research Center
      • Centerville, Ohio, Forente stater, 45459
        • Valley Medical Research
      • Independence, Ohio, Forente stater, 44131
        • Insight Clinical Trials
    • Oregon
      • Portland, Oregon, Forente stater, 97210
        • Summit Headlands
    • Pennsylvania
      • Media, Pennsylvania, Forente stater, 19063
        • Suburban Research Associates
      • Plymouth Meeting, Pennsylvania, Forente stater, 19462
        • K2 Keystone
    • Rhode Island
      • East Providence, Rhode Island, Forente stater, 02914
        • Rhode Island Mood and Memory Research Institute
    • South Carolina
      • Summerville, South Carolina, Forente stater, 29486
        • Palmetto Primary Care & Specialty Physicians
    • Tennessee
      • Cordova, Tennessee, Forente stater, 38018
        • Neurology Clinic, P.C.
      • Nashville, Tennessee, Forente stater, 37204
        • K2 Medical Research Nashville
    • Texas
      • Austin, Texas, Forente stater, 78757
        • Senior Adults Specialty Research
      • Houston, Texas, Forente stater, 77094
        • NeuroMind Clinical Trials
      • Round Rock, Texas, Forente stater, 78681
        • Central Texas Neurology Associates
      • Wichita Falls, Texas, Forente stater, 76309
        • Grayline Research Center
    • Vermont
      • Bennington, Vermont, Forente stater, 05201
        • Memory Clinic, Inc.
    • Virginia
      • Arlington, Virginia, Forente stater, 22205
        • Sana Research
      • Fairfax, Virginia, Forente stater, 22031
        • Re:Cognition Fairfax

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

55 år til 85 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Diagnosis of AD according to the 2024 National Institute on Aging and Alzheimer's Association criteria.

  2. Male or female, aged 55 - 85 years.

  3. MMSE 20-28 at screening and baseline.

  4. CDR global score=0.5 or 1, with memory box score at least 0.5 at screening and baseline.

  5. Positive for amyloid beta as defined by plasma p-tau217 level at screening.

  6. Neuroimaging (MRI) consistent with the clinical diagnosis of AD and without findings of significant exclusionary abnormalities (see exclusion criteria # 4). A historical MRI, up to 1 year prior to screening, may be used as long as there have been no interval clinical neurologic events that may suggest a change in the MRI scan.

  7. Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week) and will accompany the participant on study visits at designated times.

  8. Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:

    • Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,

    • Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,

    • Intrauterine device (IUD),

    • Intrauterine hormone-releasing system (IUS),

    • Bilateral tubal occlusion,

    • Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant. If not, an additional highly effective method of contraception should be used),

    • Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).

      • Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.
  9. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:

    • Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
    • Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
    • IUD,
    • IUS,
    • Bilateral tubal occlusion.
  10. General cognition and functional performance sufficiently preserved that the subject can provide written informed consent. At re-consent, a legally authorized representative may co-sign if participants do not meet the general cognition and functional performance needed in the opinion of the investigator.

  11. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the Columbia Suicide Severity Rating Scale.

  12. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section for details on prohibited and permitted medications.

    • Cholinesterase inhibitors and/or memantine medication,
    • Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure in 3 years prior to screening
    • Mood-stabilizing psychotropic agents including, but not limited to, lithium.
  13. Adequate visual and hearing ability (physical ability to perform all the study assessments).

  14. Participants previously exposed to buntanetap can still be included in the study after a 28-day wash out period.

Exclusion Criteria:

  1. Has a history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRI) or other anti-depression medication (e.g. Wellbutrin) at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  2. Has non-AD dementia, such as vascular dementia, Lewy body dementia, frontotemporal disease, PD dementia, B12 and thyroid deficiency caused dementia.

  3. History of a seizure disorder, if stable on medication is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  4. Screening MRI (or historical MRI, if applicable) of the brain indicative of significant abnormality, including, but not limited to, prior hemorrhage (>5) or infarct > 1 cm3, > 3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g., abscess or brain tumor such as meningioma unless they are documented and stable).

  5. Has a history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women ((in the absence of a bundle branch block), or torsades de pointes.

  6. Has bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.

  7. Has uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the PI believes the participant's diabetes is under control.

  8. Has clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) <50 mL/min/BSA (body surface area) or hepatic impairment (alkaline phosphatase (ALP) > 2.0 ULN and/or total bilirubin > 2.0 ULN).

  9. Has any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase (AST) or alanine aminotransferase (ALT)) greater than twice the upper limit of normal will be excluded.

  10. Is at imminent risk of self-harm, based on clinical interview and responses on the C- SSRS, or of harm to others in the opinion of the PI. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to items 4 or 5 in assessment of suicidal ideation on the C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.

  11. Has cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).

  12. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version DSM.

  13. Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.

  14. Participants with learning disability or developmental delay.

  15. Participants whom the PI deems to be otherwise ineligible.

  16. Participants with a known allergy to the investigational drug or any of its components.

    Inactive ingredients of the investigational medicinal product:

    • Silicified Microcrystalline Cellulose
    • Dibasic Calcium Phosphate Dihydrate
    • Mannitol
    • Stearic Acid
    • Hypromellosee (capsule shells structure)
    • Titanium dioxide (opacifier of the capsule shells)
  17. Participant is currently pregnant, breast-feeding, and/or lactating.

  18. Participant is currently taking strong and moderate CYP3A4 inhibitors and/or inducers. Refer to Concomitant Medications section below for details on prohibited and permitted medications.

  19. Participants with uncontrolled hypertension (systolic >160mm Hg and/or diastolic >95mm Hg) or hypotension (systolic <90mm Hg and/or diastolic <60 mm Hg) and deemed medically significant by the PI.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo

Placebo capsule by mouth once daily for 18 months

Eksperimentell: buntanetap

30mg capsule by mouth once daily for 18 months

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13)
Tidsramme: From screening to 6-month readout, to end of treatment at 18 months.

ADAS-Cog13 includes the original ADAS-Cog11 items that assess cognitive function across the memory, language, praxis, and orientation domains and adds a number cancellation task and a delayed free recall task. Total scores range from 0-85, with higher scores indicating greater cognitive impairment.

From screening to 6-month readout, to end of treatment at 18 months.
Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-iADL)
Tidsramme: From screening to 6-month readout, to end of treatment at 18 months.

The Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL) is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's study partner to assess function to the degree to which the participant can perform a variety of tasks. The questionnaire asks 6 questions of basic ADLs and 17 instrumental ADLs. The iADL are more complex tasks, including activities such as shopping, maintaining appointments, or managing one's belongings or finances. The ADCS-iADL subset is assessed with items 6a and 7-23; scores range from 0 to 59, with lower scores indicating greater impairment in function.

From screening to 6-month readout, to end of treatment at 18 months.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

4. februar 2025

Primær fullføring (Antatt)

1. desember 2027

Studiet fullført (Antatt)

1. juni 2028

Datoer for studieregistrering

Først innsendt

26. november 2024

Først innsendt som oppfylte QC-kriteriene

26. november 2024

Først lagt ut (Faktiske)

29. november 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

19. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere